Senate Markup Of Controversial Patent Bills Now Set For Thursday

The Senate Judiciary Committee has rescheduled a postponed markup of two patent reform bills for Thursday (Sept. 26) that aim to improve the patent eligibility process and the tribunal review of patents, but the changes are opposed by the generic drug industry and key drug price reform advocates. The committee will mark up S. 2220, the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act, and S. 2140, the Patent Eligibility Restoration Act (PERA), along with several other...